News

CUTISS has been granted a new patent in the United States for automated methods and systems for producing skin grafts. The patent (U.S. Patent No. 12,599,401 B2), titled “Methods and systems for producing skin grafts”, covers automated methods and systems for skin graft production, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow in which a skin biopsy may be separated into dermis and epidermis, fibroblasts and keratinocytes isolated and expanded, and a skin graft formed under automated control. The patent was granted on April 14, 2026, and is assigned to CUTISS AG. According to the patent, this approach is intended to support a more reproducible, reliable, and efficient manufacturing process. It further strengthens CUTISS’ intellectual property portfolio in regenerative medicine and tissue bioengineering, and supports the company’s broader strategy to advance standardized and scalable manufacturing for personalized skin tissue therapy. Newsroom

A new peer-reviewed publication reports 1-year results from a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial evaluating denovoSkin™ in reconstructive surgery in patients of all ages. The study evaluated denovoSkin™ against autologous split-thickness skin grafts (STSG) in 23 patients with full-thickness skin defects requiring planned elective reconstruction. According to the publication, denovoSkin™ demonstrated significantly better scar quality than STSG at 3 months, with benefits maintained at 12 months. Elasticity parameters also consistently favored denovoSkin™, and significant donor site sparing was also demonstrated. The authors conclude that denovoSkin™ is a safe and effective treatment for full-thickness skin defects and provides favorable skin quality over 12 months.  The study was conducted across sites in Italy, the Netherlands and Switzerland. denovoSkin™ was manufactured under GMP conditions, first at Wyss Zurich and thereafter at CUTISS in Schlieren, Switzerland.  This publication adds to the growing body of clinical evidence supporting denovoSkin™ as a personalized, bio-engineered dermo-epidermal skin graft for the treatment of acute and elective full-thickness skin defects. The paper, published in the Journal of Tissue Engineering, is titled “Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial” and can be found online here. Our clinical development pipeline is available here. Newsroom Publication

CUTISS has been granted a new patent in the United States for a disposable system and method used in the preparation of compressed hydrogels for tissue engineering applications. The patent (U.S. Patent No. 12,564,662 B2), titled “Disposable system and method for preparing a compressed hydrogel”, protects a fully disposable system for casting, polymerizing and compressing a hydrogel, as well as methods for producing a scaffold for the generation of artificial tissue products, including skin grafts. The patent was granted on March 3, 2026, and is assigned to CUTISS AG, Schlieren. The patented invention relates to a core part of the tissue engineering process by enabling the preparation of compressed hydrogels in a fully disposable format. According to the patent, this approach is designed to reduce contamination risk, simplify workflow, lower production complexity and support improved quality and scalability in graft manufacturing. This new U.S. patent further strengthens CUTISS’ intellectual property portfolio in regenerative medicine and tissue bioengineering. It also supports the company’s broader strategy to industrialize personalized skin tissue therapy through robust, standardized and scalable manufacturing approaches for denovoSkin™, CUTISS’ lead product currently in late-stage clinical development in Switzerland and the European Union. denovoSkin™ is currently in Phase 3 clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. Newsroom

A new peer-reviewed report in the Journal of Burn Care & Research describes the compassionate use of denovoSkin™ in a pediatric patient with extensive burn injuries treated at Massachusetts General Hospital (Boston, USA). The publication details reconstructive procedures including contracture release and treatment of unstable scars, reporting high engraftment rates, durable healed skin, and handling characteristics comparable to full-thickness autografts. This report provides additional clinical detail following the first U.S. compassionate use announced in 2024 and the abstract presented in 2025. In parallel, CUTISS continues to advance denovoSkin™ in an ongoing Phase 3 clinical trial in the European Union (8 countries) and Switzerland for adult and adolescent patients with severe burns. Our clinical development pipeline is available here. The published report can be accessed online here. Newsroom Report

CUTISS is pleased to share that the 1-year results of the Phase IIb clinical trial evaluating denovoSkin™ in adolescent and adult burn patients have been published in eClinicalMedicine, part of The Lancet Discovery Science. The prospective, randomized, controlled multicenter study compared denovoSkin™ to split-thickness skin grafts, the current surgical standard. The efficacy readout shows that denovoSkin™ demonstrated a markedly higher expansion capacity from a small biopsy, and a minimally scarring outcome, in sharp contrast to the intra-patient control. These outcomes support the potential of denovoSkin™ to safely reduce donor-site burden and improve long-term scar quality in severe burn care. This publication represents a very important milestone for CUTISS and contributes robust clinical evidence to the field of personalized, bio-engineered skin replacement. The study was conducted in four burn centers across Switzerland, the Netherlands, and Italy, with manufacturing performed in CUTISS’ state-of-the-art GMP (Good Manufacturing Practice) facility in Zurich. The clinical follow-up for this Phase IIb study recently completed the 3-year follow up period. You can access the published paper online here Ongoing clinical development program In parallel, CUTISS’ Phase IIb study on pediatric burns is ongoing and will soon hit the 1-year readout. The reconstructive Phase II clinical trial recently reached the 2-year follow-up readout, further expanding the clinical evidence base for denovoSkin™ in elective skin surgery. denovoSkin™ also continues to advance in its Phase III clinical trial in adolescents and adults across the EU and in Switzerland.  Newsroom Published paper

CUTISS has completed an interim analysis in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns, with positive results. The randomized, controlled trial enrolled 12 pediatric patients, comparing denovoSkin™ to the current standard of care (autografting) using an intra-patient control design. The results from the interim analysis confirm a favorable safety profile and show positive signals of efficacy, supporting the continued development of denovoSkin™ for use in pediatric burn care. Children with extensive burns are particularly vulnerable to complications related to scarring, such as impaired growth and mobility, and visible disfigurement. The findings of this study, together with the results obtained in several pediatric compassionate burn patients, represent an important step in pediatric skin surgery, aiming to offer a personalized, donor site-sparing solution that also addresses the lifelong impact of scarring on quality of life. The 1 year analysis of the trial will follow; the trial has a total of 3 years of follow-up. In parallel, CUTISS is advancing denovoSkin™ in a Phase 3 clinical trial for adolescents and adults with severe burns in the E.U. and Switzerland, as detailed in our news on 6 May 2025. Newsroom Read News from 6 may 25

The abstract published in the Journal of Burn Care & Research (March/April 2025) by the American Burn Association (57th annual meeting) describes the compassionate use of denovoSkin™ in reconstructive surgery for a three-year-old child with 90% total body surface area (TBSA) burn injuries at Massachusetts General Hospital, a leading U.S. burn center. The treatment was carried out under a compassionate use exemption from the U.S. FDA. The case involved contracture release surgeries and treatment of non-healed wounds and unstable scars. The denovoSkin™ grafts demonstrated an engraftment rate greater than 95%, with the resulting skin described as durable and manageable, comparable to traditional full-thickness autografts but with advantages over conventional cultured epidermal autografts (CEAs). The authors conclude that this use of denovoSkin™ introduces a new treatment paradigm in both acute and reconstructive burn surgery, especially for patients with extensive injuries and limited donor skin. This case report adds to the growing body of clinical experience supporting denovoSkin™ as a potential breakthrough in skin tissue therapy, including in pediatric reconstructive care under extreme conditions. As the paper’s authors note: “The development of an autologous, full-thickness skin replacement remains the holy grail for the treatment of full thickness skin loss from burns, wounds, and trauma.” The abstract can be read online here: Burn Care & Research  Full citation: Matthew Supple, Robert Sheridan, Jeremy Goverman, 846 Pediatric Compassionate Use of a Novel, Autologous, Engineered, Hydrogel Skin Graft with Keratinocytes and Fibroblasts, Journal of Burn Care & Research, Volume 46, Issue Supplement_1, March/April 2025, Page S288. Newsroom Read Article

CUTISS has completed patient recruitment in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns. This randomized, controlled trial compares denovoSkin™ to the current standard of care, autografting, using an intra-patient control design. It is one of three Phase 2 trials designed to assess denovoSkin™ – a personalized, bioengineered skin graft – across different patient populations and indications. denovoSkin™ has also been used to treat children on a compassionate use basis where existing therapies are not sufficient or suitable. Severe burns in children are associated with lifelong consequences, including scarring and restricted growth. By generating clinical evidence in pediatric patients, this study supports the broader development of denovoSkin™ as a skin tissue therapy designed to reduce donor site burden and improve long-term scar outcomes. With recruitment now completed, the study moves into follow-up and data analysis. Results will contribute to the broader clinical development program of denovoSkin™, currently in Phase 3 for adolescents and adults. In February 2025, CUTISS announced positive long-term efficacy and safety readout in the Phase 2 clinical trials of denovoSkin™ in reconstructive surgery as well as in burns treatment (press release available here). Newsroom

CUTISS is making steady progress in the clinical development of denovoSkin™, its personalized, bio-engineered skin graft, as part of the ongoing Phase 3 clinical trial for the treatment of severe burns. The first enrolled patients have now been successfully grafted with denovoSkin™ at clinical sites in the Netherlands and Spain, with additional recruitment underway in France and Italy. There are eight sites involved in this confirmatory study in the EU. In parallel, the trial has also been approved in Switzerland by Swissmedic, with preparations in place to begin patient recruitment. We thank the clinical teams, surgeons, patients, collaborators, and stakeholders whose work and dedication is driving this important progress. Newsroom

CUTISS has been granted a new patent in the United States for a core element of its automated platform used to manufacture personalized, bio-engineered human skin grafts. The patent (US Patent No. 12,286,611), titled “Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems,” protects a key component of the company’s automated tissue engineering process for denovoSkin™, currently in late-stage clinical development for skin surgery. This patent supports CUTISS’ broader strategy to industrialize personalized skin tissue therapy through standardization, reproducibility, and scalability. The company’s automation efforts have been commenced in collaboration with CSEM and INNOSUISSE and are now being advanced in collaboration with Tecan (read our partnership announcement here), a global leader in laboratory automation. The granting of this U.S. patent further strengthens our international intellectual property portfolio in the field of regenerative medicine and tissue bio-engineering. Newsroom Read Press release